Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.49 |
| ▸ | AMD1 | P17707 | 2/20 | 0.48 |
| ▸ | DOT1L | Q8TEK3 | 7/20 | 0.47 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15509300 | 1.00 | PI4KA (0.54) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL23776568 | 1.00 | PI4KA (0.54) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9106917 | 1.00 | PI4KA (0.54) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9913520 | 1.00 | PI4KA (0.54) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL30277435 | 1.00 | PI4KA (0.54) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL18648520 | 0.96 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9105206 | 0.91 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9105267 | 0.91 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9913608 | 0.91 | PI4KA (0.58) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9106847 | 0.91 | PI4KA (0.58) | PI4KAPI4K2BPI4K2API4KBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11603570-B2 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-03-14 | — | — | US | disclosed |
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-10881680-B2 | Method of treating leukemia | Epizyme, Inc. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200239963-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3027774-B1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10407732-B2 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190216838-A1 | METHOD OF TREATING LEUKEMIA | Epizyme, Inc. | 2019-07-18 | — | — | US | disclosed |
| US-20180280422-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2018-10-04 | — | — | US | disclosed |
| US-9597348-B2 | Method of treating leukemia | Epizyme, Inc. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160298195-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MEMORIAL SLOAN KETTERING CANCER CENTER | 2016-10-13 | — | — | US | disclosed |
| EP-2646444-B1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES | EPIZYME INC (US) | 2016-03-16 | — | — | EP | disclosed |
| EP-2646444-B1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES | EPIZYME INC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150216890-A1 | METHOD OF TREATING LEUKEMIA | Epizyme, Inc. (US) | 2015-08-06 | — | — | US | disclosed |
| US-9096634-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140051654-A1 | Substituted Purine and 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8580762-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580762-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280422-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | PI4KA 3070/4885PI4K2B 3345/4885PI4K2A 3188/4885 |
| US-10881680-B2 | Method of treating leukemia | DOT1L, MCL1, CARM1 | PI4KA 2351/4885PI4K2B 2334/4885PI4K2A 2248/4885 |
| US-20150216890-A1 | METHOD OF TREATING LEUKEMIA | DOT1L, MCL1, CARM1 | PI4KA 2351/4885PI4K2B 2334/4885PI4K2A 2248/4885 |
| US-20190216838-A1 | METHOD OF TREATING LEUKEMIA | DOT1L, MCL1, CARM1 | PI4KA 2351/4885PI4K2B 2334/4885PI4K2A 2248/4885 |
| US-11603570-B2 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition | MLLT1, MCL1, BCR | PI4KA 3164/4885PI4K2B 2613/4885PI4K2A 2893/4885 |
| US-10407732-B2 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition | MLLT1, MCL1, BCR | PI4KA 3675/4885PI4K2B 3671/4885PI4K2A 3793/4885 |
| US-20160298195-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MLLT1, MCL1, BCR | PI4KA 3675/4885PI4K2B 3671/4885PI4K2A 3793/4885 |
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | PI4KA 3070/4885PI4K2B 3345/4885PI4K2A 3188/4885 |
| US-20200239963-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION | MLLT1, MCL1, BCR | PI4KA 3164/4885PI4K2B 2613/4885PI4K2A 2893/4885 |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | PI4KA 3070/4885PI4K2B 3345/4885PI4K2A 3188/4885 |
| US-20140051654-A1 | Substituted Purine and 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | PI4KA 3070/4885PI4K2B 3345/4885PI4K2A 3188/4885 |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | PI4KA 3070/4885PI4K2B 3345/4885PI4K2A 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.